Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05335356 · ClinicalTrials.gov registry record · Phase 3
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3 study of Moderate-to-severe Chronic Plaque Psoriasis, sponsored by Biocon Biologics UK.
- Completed
- Registry status
- Phase 3
- Development phase
- 384
- Enrollment target
- 1
- Study location
NCT05335356 is a Phase 3 study of Moderate-to-severe Chronic Plaque Psoriasis that has completed, run by Biocon Biologics UK. The registered enrollment target is 384 participants, above the 100-participant average among 3 other Moderate-to-severe Chronic Plaque Psoriasis trials with a reported enrollment target (284% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05335356, a Phase 3 study of Moderate-to-severe Chronic Plaque Psoriasis, has completed, sponsored by Biocon Biologics UK.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 384 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, active-controlled, parallel-group, multicenter study designed to compare the efficacy, safety, immunogenicity, and PK(Pharmacokinetic) of Bmab 1200 with Stelara in adult patients with moderate to severe chronic plaque psoriasis.
Conditions Studied
Interventions
- BIOLOGICAL Stelara
- BIOLOGICAL Bmab1200
Study Locations (1)
Ohio
- Apex Clinical Research Center - Mayfield Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 384 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2023-11-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05335356
The ClinicalTrials.gov registry entry for NCT05335356 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 384 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 100-participant average among 3 other Moderate-to-severe Chronic Plaque Psoriasis trials with a reported enrollment target (284% higher). The listed sponsor is Biocon Biologics UK, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate-to-severe Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Stelara is the first listed.
NCT05335356 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05335356 about?
NCT05335356 is a clinical study titled "Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis". This is a randomized, double-blind, active-controlled, parallel-group, multicenter study designed to compare the efficacy, safety, immunogenicity, and PK(Pharmacokinetic) of Bmab 1200 with Stelara in adult patients with moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT05335356?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 384 participants. The study started on 2022-06-28. Estimated completion is 2023-11-15.
What conditions does trial NCT05335356 study?
This clinical trial studies the following conditions: Moderate-to-severe Chronic Plaque Psoriasis.
What interventions are being tested in trial NCT05335356?
The interventions under investigation include: Stelara (BIOLOGICAL), Bmab1200 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05335356?
This trial is sponsored by Biocon Biologics UK, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05335356 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate-to-severe Chronic Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.